Rock Springs Capital Management LP Sells 15,249 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Rock Springs Capital Management LP lowered its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,034,137 shares of the company's stock after selling 15,249 shares during the quarter. Kymera Therapeutics comprises approximately 1.6% of Rock Springs Capital Management LP's investment portfolio, making the stock its 20th biggest holding. Rock Springs Capital Management LP owned 1.60% of Kymera Therapeutics worth $41,603,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the period. Summit Investment Advisors Inc. raised its holdings in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after purchasing an additional 406 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Kymera Therapeutics by 1.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock valued at $1,649,000 after purchasing an additional 684 shares in the last quarter. KBC Group NV increased its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company's stock valued at $552,000 after buying an additional 1,311 shares during the period.

Insiders Place Their Bets

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company's stock, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 over the last ninety days. Corporate insiders own 15.82% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on KYMR shares. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Stephens restated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. HC Wainwright upped their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Citigroup began coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock traded down $0.30 during mid-day trading on Friday, hitting $33.26. 500,969 shares of the company's stock traded hands, compared to its average volume of 555,757. The firm has a 50 day simple moving average of $29.89 and a two-hundred day simple moving average of $38.61. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -14.21 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. On average, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.